Aspen Neuroscience seeks up to $155M in its Nasdaq IPO to fund a Phase III trial of its iPSC-derived cell therapy for ...
Genmab's petosemtamab met its main goals in a Phase III head and neck cancer trial and is heading to regulators. Read what the results mean for patients.
Researchers at Huazhong Agricultural University have developed AbOptimizer, a reinforcement-learning framework that proposes ...
LYNK Pharmaceutical's zemprocitinib sustained ACR20 response above 91% in Phase III rheumatoid arthritis trial. Discover the full long-term results and ...
Astellas secures an exclusive option to license Audax's DAX-044, a preclinical IL-12 cancer antibody, in a deal worth up to ...
Novartis takes a $1.9B delgocitinib writedown after a Duchenne failure as remibrutinib nears FDA filing in MS. Read the full ...
Nxera exercises its option for exclusive rights to Idorsia's lucerastat for Fabry disease in Japan and Asia ex-China. Read ...
Oruka's ORKA-001 hit 61% complete skin clearance in Phase IIb EVERLAST-B psoriasis trial. Phase III. Read the full results ...
Insilico's AI-designed pan-TEAD inhibitor ISM6331 posted a 40% objective response rate at 130 mg in early mesothelioma data.
Rhode Island and Massachusetts life science groups sign MOU to plan a shared regional biobank for brain disease research.
Teva acquires worldwide rights to BXCL501 sublingual film from BioXcel: $57.5M upfront, up to $125M total. Read the full deal ...
GSK's Ris-Rez cut progression or death risk 67% vs chemotherapy in relapsed osteosarcoma. Read the Phase III results and what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results